SNDX - NASDAQ

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc.

SNDXยทNASDAQ

$18.34

-2.7%
HealthcareBiotechnology

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.63B
EPS-3.2900
P/E Ratio-5.57
Earnings Date08/03/2026
Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. Fair Value Envelope

SNDX ยท NASDAQ

Our analysis suggests that SNDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $18.34, this represents a potential HIDDEN relative to our calculated worth for Syndax Pharmaceuticals, Inc..

HIDDEN
Intrinsic Value
Current Price: $18.34

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$972.0M
+ Cash & Equivalents$134.9M
Firm Value-$837.1M
- Debt$346.5M
Equity Value-$1.2B
/ Shares Outstanding86,550,544B
DCF Value-$14
OVERVALUED BY 175%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$266.3M
-$219.5M
-$181.0M
-$149.2M
-$123.0M
-$101.4M
-$83.6M
-$68.9M
-$56.8M
-$46.9M
Maintenance CapEx
-$30.8K
-$25.4K
-$21.0K
-$17.3K
-$14.2K
-$11.7K
-$9.7K
-$8.0K
-$6.6K
-$5.4K
Owner Earnings
-$266.3M
-$219.6M
-$181.0M
-$149.2M
-$123.0M
-$101.4M
-$83.6M
-$68.9M
-$56.8M
-$46.9M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$246.6M
-$188.2M
-$143.7M
-$109.7M
-$83.7M
-$63.9M
-$48.8M
-$37.2M
-$28.4M
-$21.7M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your SNDX research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.